RA Capital buys 2.84M Hemab Therapeutics shares
Hemab Therapeutics Holdings, Inc. reported that funds managed by RA Capital increased their indirect stake through a mix of open‑market purchases and preferred stock conversions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. reported that funds managed by RA Capital increased their indirect stake through a mix of open‑market purchases and preferred stock conversions. Over May 4–6, 2026, the funds bought 2,840,429 shares of common stock at prices including $18.00, $24.59, $25.00, $23.77 and $24.83 per share. In connection with the issuer’s initial public offering, all Series A, B and C preferred shares automatically converted to common stock on a 22‑for‑1 basis for no additional consideration. Following these transactions, indirect holdings reported in one line reached 6,314,525 shares of common stock.
Insider Trade Summary
Net Buyer: 2,840,429 shares
Net Buy
15 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund IV, L.P., Kolchinsky Peter, Shah Rajeev M.
Role
Director, 10% Owner | Director, 10% Owner | Director | Director | Director, 10% Owner | Director, 10% Owner
Bought
2,840,429 shs ($52.22M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 14,611 | $23.77 | $347K |
| Purchase | Common Stock | 53,407 | $24.83 | $1.33M |
| Purchase | Common Stock | 87,143 | $24.59 | $2.14M |
| Purchase | Common Stock | 10,268 | $25.00 | $257K |
| Conversion | Series A Preferred Stock | 64,680 | $0.00 | $0.00 |
| Conversion | Series A Preferred Stock | 27,720 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock | 42,341 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock | 18,146 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock | 56,972 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock | 10,054 | $0.00 | $0.00 |
| Conversion | Common Stock | 3,607,846 | $0.00 | $0.00 |
| Conversion | Common Stock | 1,009,052 | $0.00 | $0.00 |
| Conversion | Common Stock | 221,188 | $0.00 | $0.00 |
| Purchase | Common Stock | 2,541,250 | $18.00 | $45.74M |
| Purchase | Common Stock | 133,750 | $18.00 | $2.41M |
Holdings After Transaction:
Series A Preferred Stock — 0 contracts (Indirect, See footnotes);
Series B Preferred Stock — 0 contracts (Indirect, See footnotes);
Series C Preferred Stock — 0 contracts (Indirect, See footnotes);
Common Stock — 6,314,525 shares (Indirect, See footnotes)
Footnotes (8)
- F1. Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
- F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F3. Held directly by the Fund.
- F4. Held directly by Nexus Fund II.
- F5. Held directly by Nexus Fund IV.
- F6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.495 to $24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F8. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.505 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Key Figures
Open-market purchases: 2,840,429 shares
Highest reported purchase price: $25.00 per share
Large single-day buy: 2,541,250 shares at $18.00
+5 more
8 metrics
Open-market purchases
2,840,429 shares
Net common stock bought May 4–6, 2026
Highest reported purchase price
$25.00 per share
Common stock transaction on May 5, 2026
Large single-day buy
2,541,250 shares at $18.00
Common stock purchased May 4, 2026 across two lines
Conversion ratio
22-for-1
Series A, B, C preferred converting to common before IPO
Indirect holdings after trade
6,314,525 shares
Common stock held indirectly after May 6, 2026 purchase
Series C conversion block
1,253,572 common shares
221,188 and 1,253,384 underlying shares from Series C preferred
Series B conversion block
1,330,714 common shares
399,212 and 931,502 underlying shares from Series B preferred
Series A conversion block
2,032,800 common shares
609,840 and 1,422,960 underlying shares from Series A preferred
Key Terms
weighted average price, initial public offering, pecuniary interest, derivative security, +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
initial public offering financial
"converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
pecuniary interest financial
"disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein"
derivative security financial
"Conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
conversion of derivative security financial
"transaction_code_description": "Conversion of derivative security""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did RA Capital report in Hemab Therapeutics (COAG)?
RA Capital-managed funds reported open-market purchases and preferred stock conversions in Hemab Therapeutics. They acquired common shares through multiple buys in early May 2026 and automatic 22-for-1 conversions of Series A, B and C preferred stock immediately before the company’s initial public offering.
What happened to Hemab Therapeutics (COAG) preferred stock in this Form 4?
All Series A, Series B and Series C preferred stock automatically converted into Hemab Therapeutics common stock immediately before the initial public offering. The conversion occurred at a 22-for-1 ratio for no additional consideration and the preferred shares had no expiration date before conversion.
What was the resulting Hemab Therapeutics (COAG) position after these RA Capital transactions?
One reported line shows indirect holdings of 6,314,525 Hemab Therapeutics common shares following a May 6, 2026 purchase. Other lines show different post-transaction share counts for specific entities, reflecting positions held by individual RA Capital-managed funds after the various buys and conversions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
